LDR Prostate
Brachytherapy
Program
A comprehensive solution for ACS-based Urology practices
How can an LDR Prostate Brachytherapy Program benefit your practice?
Program Overview
WRO integrates with partner Urology practices to provide a seamless, end-to-end solution for delivering Low Dose Rate (LDR) prostate brachytherapy.
Our board-certified Radiation Oncologists deliver expert clinical care while also handling regulatory compliance, program setup, staffing, equipment, and ongoing management—so your practice can expand patient services with minimal burden.
Treatment Benefits
Low Dose Rate (LDR) brachytherapy offers your patients many benefits compared to traditional external beam radiation therapy. 1
LDR brachytherapy doubles the cure rate for patients with high-risk prostate cancer, as compared to conventional EBRT alone.
LDR brachytherapy can deliver millimeter-level precision and accuracy to sculpt the radiation dose to the patient’s specific anatomy and "dose-escalate" to areas of concern while minimizing radiation dose to surrounding tissues.
Conventional radiation therapy may require daily sessions for several weeks, while LDR brachytherapy is a one-time outpatient procedure.
The precision of LDR brachytherapy leads to limited side effects and a reduced risk of complications, such as urinary incontinence and erectile dysfunction.
Most men return to their normal lives the day after the procedure with minimal to no pain or discomfort.
Get Started
Contact us today for more information on how our LDR brachytherapy program can seamlessly integrate into your urology practice.
We look forward to being your trusted partner in delivering state-of-the-art LDR prostate brachytherapy to the patients who need it most.
References:
- Morris, W James et al. “Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.” International journal of radiation oncology, biology, physics vol. 98,2 (2017): 275-285. doi:10.1016/j.ijrobp.2016.11.026
This overview is for informational purposes only and is based on our Professional Services Agreement. Full details, including specific obligations, compensation, and compliance requirements, are contained in the executed contract.